Login to Your Account

Palatin Crushed On ED Trials Delay; FDA Cites Safety Concerns

By Jennifer Boggs

Friday, August 31, 2007
News of a delay in the start of pivotal trials of bremelanotide in erectile dysfunction - and the possibility that safety concerns could limit the drug's use in that indication - sent shares of Palatin Technologies Inc. plunging more than 60 percent. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription